Clik here to view.
エクセンシアが3月に開催される投資家会議に参加
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq：EXAI）は本日、経営陣が近く3月に開催される下記の投資家会議に参加すると発表しました： モルガン・スタンレーEMEAヘルステック会議：2023年3月1日（水）のバーチャル投資家会議に経営陣が参加...
View ArticleClik here to view.
Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in...
CRANBURY, N.J. & SHANGHAI Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first...
View ArticleClik here to view.
冰洲石生物自主研发的创新雄激素受体嵌合降解剂AC0176在中国成功完成第一例病人首次给药
美国新泽西 & 中国上海 (美国商业资讯)–冰洲石生物（Accutar Biotechnology, Inc.），一家专注于人工智能药物研发的临床阶段生物技术公司，今天宣布完成了AC0176在中国的1期临床研究第一例病人首次给药。这例病人在北京大学肿瘤医院入组并给药。...
View ArticleClik here to view.
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first subject has been dosed in clinical trial of ICP-B05 (CM369), an anti-CC...
View ArticleClik here to view.
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the China National Medical Products...
View ArticleClik here to view.
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen’s...
View ArticleClik here to view.
China Performs First Cancer Patient Treatments in the Xiamen Humanity...
XIAMEN, China Neuboron Medical Group (NMG), a leading global Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) total solution provider today announced that the first AB-BNCT cancer research...
View ArticleClik here to view.
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth...
View ArticleClik here to view.
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing...
View ArticleClik here to view.
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has...
View ArticleClik here to view.
COGNANO, Inc.: Statistical Discovery of Triple-negative Breast...
KYOTO, Japan COGNANO, Inc. (Kyoto, Japan) and associates announced the discovery of a panel of antibodies specific for triple-negative breast cancer (TNBC). Breast cancer was the second leading...
View ArticleClik here to view.
知临集团宣布与美国 FDA成功举办关于SACT-1（一种针对神经母细胞瘤的再利用小分子药物）完结临床1期试验的会议
NEW YORK & LONDON & PARIS 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）（「知临集团」或「知临」），一家处于临床阶段的生物制药公司，宣布与美国食品和药物管理局(「美国 FDA」)成功举办一项药物完结临床1期试验的讨论会议。 SACT-1是一种再利用的小分子药物，配制为口服混悬液，靶向儿科神经母细胞瘤患者，已获得了美国...
View ArticleClik here to view.
知临集团宣布完成与美国食品藥物管理局就申请首创小分子药物ALS-4靶向耐甲氧西林金黄色葡萄球菌临床试验前的讨论会
NEW YORK & LONDON & PARIS (美国商业资讯)–...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8010, an...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8008, an...
View ArticleClik here to view.
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of...
TOKYO Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head...
View ArticleClik here to view.
Exscientia宣布与Charité合作推进精准医学平台的开发
英国牛津和德国柏林 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天宣布与Charité – Universitätsmedizin Berlin (Charité)建立新的合作关系，将Exscientia的人工智能精准医疗平台应用于血液癌症。...
View ArticleClik here to view.
Prestige Biopharma Develops First-in-Class PAUF-detecting Diagnostic Kit, a...
SINGAPORE Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has developed a first-in-class diagnostic kit for pancreatic cancer. Pancreatic cancer is a characteristically...
View ArticleClik here to view.
エクセンシアが精密医療プラットフォームの開発促進に向けてシャリテとの連携を発表
英オックスフォード & 独ベルリン （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は本日、血液がんにおけるエクセンシアのAI駆使型精密医療プラットフォームの活用に向け、シャリテ・ベルリン医科大学（シャリテ）との新たな提携を発表しました。...
View ArticleClik here to view.
Teva and Natco Announce Launch of additional strengths for the Generic...
PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE:...
View Article